WOBURN, Mass.--(BUSINESS WIRE)--ArQule, Inc. (NASDAQ: ARQL) today announced the expansion of its clinical development program for ARQ 197, a proprietary, orally administered small molecule inhibitor of the c-Met receptor tyrosine kinase, with a new target indication, hepatocellular carcinoma (HCC). ArQule and Daiichi Sankyo Co. Ltd. (TSE: 4568) signed a license, co-development and co-commercialization agreement in December 2008 to co-develop ARQ 197.
